A Phase I, Open-Label, Single Center Trial to Investigate the Mass Balance, Metabolite Profile and Oral Bioavailability of Pimasertib in Cancer Patients With Locally Advanced or Metastatic Solid Tumors
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Pimasertib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Merck KGaA
- 01 Dec 2016 Results published in the Drug Metabolism and Disposition
- 12 May 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 16 Nov 2012 New trial record